<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth A Bauer, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jess Mandel, MD, MACP, ATSF, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James D Douketis, MD, FRCPC, FACP, FCCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with malignancy are at high risk of developing venous thromboembolism (VTE; deep venous thrombosis and pulmonary embolism). Thrombotic events are the second leading cause of death in cancer patients after death from cancer itself [
         <a href="#rid1">
          1
         </a>
         ]. Thus, timely treatment with anticoagulant therapy is critical for managing this population.
        </p>
        <p>
         Anticoagulation for acute VTE in patients with malignancy is discussed in this topic. Most of the recommendations for anticoagulation in this topic assume that treatment is in accordance with the patient's preference with regard to goals of care and life expectancy. The pathogenesis, epidemiology, and prevention of VTE in patients with malignancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis", section on 'Malignancy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">
          "Risk and prevention of venous thromboembolism in adults with cancer", section on 'Primary prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PRINCIPLES OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general principles of managing acute VTE in patients with cancer are the same as those for patients without cancer, with anticoagulant therapy as the cornerstone of treatment. However, treatment of VTE in patients with cancer has higher than usual rates of both VTE recurrence and bleeding events  (
         <a class="graphic graphic_table graphicRef81646" href="/z/d/graphic/81646.html" rel="external">
          table 1
         </a>
         ). In addition, therapy can be complicated by comorbidities, procedures, and medication interactions [
         <a href="#rid2">
          2-9
         </a>
         ].
        </p>
        <p>
         In general, our recommendations are consistent, for the most-part, with several evidence-based society guidelines [
         <a href="#rid10">
          10-20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20284877">
         <span class="h1">
          AGENT CHOICE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with cancer-associated VTE are treated with anticoagulation unless there is active bleeding or a high risk of bleeding. While many are treated as inpatients, there is a growing population of patients that are suitable for outpatient therapy, which can affect agent selection. Selecting patients and a suitable anticoagulant for outpatient therapy are discussed separately. (See
         <a class="local">
          'Outpatient therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H213235787">
         <span class="h2">
          Factors that influence agent choice
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many factors found in patients without malignancy also impact agent selection in patients with malignancy  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 2
         </a>
         ), and additional factors in patients with malignancy can affect the decision to initiate, continue, or stop anticoagulation  (
         <a class="graphic graphic_table graphicRef81646" href="/z/d/graphic/81646.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Examples include but are not limited to the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cost and convenience
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraindications to the chosen agent (eg, allergy or adverse effects)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of renal or liver failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Local availability
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Desire to avoid injections
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability to take and absorb oral or subcutaneous (SC) medications
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticipated discontinuation or reversal of anticoagulation (eg, for procedures)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clot burden
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Special conditions (eg, pregnancy, heparin-induced thrombocytopenia (see
         <a class="local">
          'Special populations'
         </a>
         below))
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cancer type and stage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of bleeding or bleeding diathesis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent arterial thrombosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once-daily versus twice-daily dosing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient preferences and alignment with patient goals of care
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Life expectancy
        </p>
        <p>
        </p>
        <p>
         Decision-making should be shared, taking into account the benefits and risks of anticoagulation with medications, life expectancy, and patient preference. For example, many patients may prefer to take an oral anticoagulant over daily injections or wish to avoid certain agents because of cost. On the other hand, the use of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and direct oral anticoagulants (DOACs) in patients with cancer can be complicated by drug interactions and diminished absorption or poor oral intake, or troublesome laboratory draws (for warfarin only). As another example, some patients willingly take therapy in the context of reasonable survival, while patients in a hospice setting may prefer to avoid or stop therapy [
         <a href="#rid21">
          21
         </a>
         ]. Further details regarding goals of care are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/95552.html" rel="external">
          "Discussing goals of care"
         </a>
         .)
        </p>
        <p>
         Estimating the bleeding risk in cancer-associated thrombosis is challenging. One study reported poor performance of several bleeding risk models [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Bleeding risk models'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2182696203">
         <span class="h2">
          Selecting among the agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Options for anticoagulation include SC low molecular weight (LMW) heparins (
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         , or
         <a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">
          tinzaparin
         </a>
         ), oral factor Xa inhibitors (ie,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         , and
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         ), the oral thrombin inhibitor
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         , intravenous (IV) or SC
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH), the synthetic SC pentasaccharide
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         , and the oral vitamin K antagonist
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         .
        </p>
        <p>
         For most hemodynamically stable patients with cancer-associated VTE who do not have severe renal insufficiency (eg, creatinine clearance &lt;30 mL/minute) or a contraindication, we prefer an oral factor Xa inhibitor rather than LMW heparin or IV UFH followed by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . Factor Xa inhibitors are frequently chosen to avoid the daily injections required for LMW heparin, although efficacy is equivalent between these agents and other factors may also weigh into this decision  (
         <a class="graphic graphic_table graphicRef81646" href="/z/d/graphic/81646.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Factors that influence agent choice'
         </a>
         above and
         <a class="local">
          'Hemodynamically unstable patients'
         </a>
         below and
         <a class="local">
          'Cancer-specific issues'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Factor Xa inhibitors
         </strong>
         – Among the factor Xa inhibitors,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         is our preferred
         <strong>
          monotherapy
         </strong>
         option (ie, administered without an initial five days of parenteral heparin). This preference is based upon a single randomized trial that reported similar efficacy and safety compared with LMW heparin [
         <a href="#rid23">
          23
         </a>
         ] and growing experience with this agent in this population; also, apixaban may carry a lower bleeding risk, particularly from the gastrointestinal (GI) tract, as compared with other oral factor Xa inhibitors (ie,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         ) [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="local">
          'Direct oral anticoagulant mono- or dual therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          Rivaroxaban
         </a>
         is another monotherapeutic factor Xa inhibitor alternative, but has only been prospectively compared with LMW heparin in a pilot study [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="local">
          'Direct oral anticoagulant mono- or dual therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As another alternative,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         can be used, but was studied for the treatment of acute VTE following initial treatment with five days of LMW heparin [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="local">
          'Direct oral anticoagulant mono- or dual therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Impacting agent selection among the oral factor Xa inhibitors are several additional issues. For example,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         and
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         are once-daily preparations, while
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         is a twice-daily preparation. We tend to avoid edoxaban and rivaroxaban in those with upper GI cancers since more bleeding has been reported with these agents compared with apixaban or LMW heparin. Rivaroxaban must be taken with food to maximize its absorption.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of factor Xa inhibitors is discussed separately. (See
         <a class="local">
          'Direct oral anticoagulant mono- or dual therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LMW heparin
         </strong>
         – Any of the LMW heparins,
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         , or
         <a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">
          tinzaparin
         </a>
         can be used. LMW heparin use as monotherapy is based on randomized trials typically comparing dalteparin or tinzaparin with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         as well as our extensive experience using chronic LMW heparin in cancer-associated thrombosis. (See
         <a class="local">
          'Low molecular weight heparin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Direct oral thrombin inhibitors (
         </strong>
         <strong>
          Dabigatran
         </strong>
         <strong>
          )
         </strong>
         – We generally do not use
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         in this population. While dabigatran has been compared with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         in patients without cancer, it has not been compared with chronic LMW heparin in patients with active cancer.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2224940093">
         <span class="h2">
          First-line options
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral factor Xa inhibitors are the preferred first-line agents for anticoagulation therapy in patients with cancer-associated thrombosis. LMW heparin is a suitable alternative with equivalent efficacy and long-standing history of use. The data to support these agents are discussed in the sections below. (See
         <a class="local">
          'Direct oral anticoagulant mono- or dual therapy'
         </a>
         below and
         <a class="local">
          'Low molecular weight heparin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H301510062">
         <span class="h3">
          Direct oral anticoagulant mono- or dual therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among the DOACs, oral factor Xa inhibitors have proven to be efficacious in the treatment of cancer-associated VTE as compared with LMW heparin, which was the previous standard of care, and with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . In addition, clinicians have gained experience and have become comfortable using factor Xa inhibitors (eg,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         ) in this patient population.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DOACs versus LMW heparin
         </strong>
         – LMW heparin has been compared with
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         [
         <a href="#rid23">
          23,27-29
         </a>
         ],
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         [
         <a href="#rid26">
          26
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         [
         <a href="#rid25">
          25,30,31
         </a>
         ].
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          Dabigatran
         </a>
         has not been specifically studied in cancer-associated thrombosis. On balance, oral factor Xa inhibitors are associated with similar or lower VTE recurrence rates with similar or slightly increased major bleeding rates compared with LMW heparin. In addition, they may be comparatively more cost-effective [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Meta-analyses
         </strong>
         – Several meta-analyses have examined the efficacy and safety of factor Xa inhibitors compared with LMW heparin [
         <a href="#rid11">
          11,33-37
         </a>
         ]. As an example, one meta-analysis of four trials that included 2894 patients with active cancer reported that DOACs lowered the risk of recurrent VTE compared with
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         (odds ratio [OR] 0.59, 95% CI 0.41-0.86) without increasing the risk of major bleeding (OR 1.34, 95% CI 0.83-2.18) [
         <a href="#rid37">
          37
         </a>
         ].
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          Apixaban
         </a>
         and
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         appeared to have the lowest risk of VTE recurrence, and
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         was associated with an increased risk of major bleeding (OR 1.73, 95% CI 1.04-3.16). Another meta-analysis of the same four studies reported similar results (recurrent VTE in 5.2 versus 8.2 percent and major bleeding in 4.3 versus 3.3 percent for factor Xa inhibitors and LMW heparin, respectively) [
         <a href="#rid35">
          35
         </a>
         ]. Mortality was no different.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Apixaban
         </strong>
         – In a randomized trial (CARAVAGGIO) of 1170 patients with active cancer and VTE, two-thirds of whom had locally advanced or metastatic disease,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         administered as
         <strong>
          monotherapy
         </strong>
         (ie, no initial treatment with LMW heparin; 10 mg twice daily for seven days followed by 5 mg twice daily for six months) was compared with
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         (200 international units [IU]/kg SC for one month followed by 150 IU/kg once daily) [
         <a href="#rid23">
          23
         </a>
         ]. Similar rates of VTE were seen in those receiving apixaban or LMW heparin (5.6 versus 7.9 percent, respectively; hazard ratio [HR] 0.63, 95% CI 0.37-1.07) without any significant difference in major bleeding (3.8 versus 4 percent; HR 0.82, 95% CI 0.40-1.69).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Among those with GI cancer, data are conflicting regarding the bleeding risk associated with
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         compared with other agents. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A post-hoc analysis of CARAVAGGIO reported no difference in the rates of bleeding among those with GI cancer (1.9 versus 1.7 percent) [
         <a href="#rid28">
          28
         </a>
         ]. The number of patients with upper GI or pancreatic/hepatobiliary cancers in CARAVAGGIO, however, was limited (4 or 7.6 percent on
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         and 5.4 or 7.4 percent on
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         , respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Another retrospective study suggested that
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         had higher rates of GI bleeding among those with luminal GI cancers compared with non-GI cancer [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The risk of major bleeding was lower in CARAVAGGIO than in the studies using
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         and
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         (see rivaroxaban and edoxaban bullets below).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Edoxaban
         </strong>
         – An open-label noninferiority randomized trial (Hokusai VTE Cancer Investigators) of 1050 patients with cancer-associated VTE compared anticoagulation with LMW heparin (
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         200 IU/kg for one month followed by 150 IU/kg for up to 12 months), with LMW heparin for five days followed by the oral factor Xa inhibitor
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         (60 mg once daily). Although there was no difference in the composite outcome of recurrent VTE and major bleeding, anticoagulation for up to 12 months (minimum six months) with edoxaban resulted in a nonsignificant reduction in the recurrence rate as compared with dalteparin (7.9 versus 11.3 percent, respectively), but at the expense of a higher rate of major bleeding (6.9 versus 4.0 percent, respectively) [
         <a href="#rid26">
          26
         </a>
         ]. However, the rate of more serious bleeding events was equal between the groups, and most of the major bleeds occurred in patients with upper GI cancers. Death was no different, occurring in 40 percent in the edoxaban group and in 37 percent in the dalteparin group.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Rivaroxaban
         </strong>
         – A pilot study (SELECT-D) randomized 406 patients to
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         (15 mg twice daily for three weeks followed by 20 mg once daily with food) given as
         <strong>
          monotherapy
         </strong>
         (ie, no initial treatment with LMW heparin) or to LMW heparin (
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         ; 200 IU/kg daily during month 1, then 150 IU/kg daily for months 2 to 6) [
         <a href="#rid25">
          25
         </a>
         ]. Rivaroxaban resulted in lower rates of recurrent VTE at six months (4 versus 11 percent). While the rate of major bleeding was similar (6 versus 4 percent), there was an excess number of clinically relevant nonmajor clinically relevant bleeds with rivaroxaban (13 versus 4 percent), especially in those with cancers of the upper GI tract.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          DOACs as a group
         </strong>
         – One randomized trial of 671 patients with VTE-related cancer (CANVAS) compared DOACs (mostly
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         or
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         ) with LMW heparin (mostly
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         ) [
         <a href="#rid38">
          38
         </a>
         ]. Rates of recurrent VTE at six months were similar between the groups (6.1 [DOACs] versus 8.8 percent [LMW heparin]). Rates of major bleeding were also similar (5.2 [DOACs] versus 5.6 percent [LMW heparin]). However, there were more clinically significant nonmajor bleeding events in patients receiving DOACs compared with LMW heparin (5.8 versus 2.6 percent). Mortality was no different between treatment groups. While the trial was pragmatic, it was unblinded, randomization was relatively late (within 30 days of the diagnosis), and adherence rates were lower with LMW heparin, which could have biased the results in favor of DOACs. In addition, an assessment of the risks and benefits of specific DOACs as compared with LMW heparin is unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DOACs (factor Xa inhibitors) versus
         </strong>
         <strong>
          warfarin
         </strong>
         – There are limited data comparing the efficacy and safety of DOACs and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         in the treatment of cancer-associated VTE. The data are largely derived from the initial randomized trials that compared oral factor Xa inhibitors with LMW heparin followed by warfarin. However, many of the included patients had a previous history of rather than "active" cancer. These trials are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Direct thrombin and factor Xa inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Limited direct data comparing DOACS with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a meta-analysis of five studies enrolling 982 participants, DOACs reduced the rate of recurrent VTE when compared with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (relative risk [RR] 0.66, 95% CI 0.33-1.31; 27 fewer to 12 more per 1000; low-certainty evidence) without any effect on survival or bleeding [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In another meta-analysis of six studies that included 1132 patients with deep venous thrombosis (DVT) and cancer, DOACs resulted in similar rates of VTE recurrence compared with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (4 versus 6 percent; OR 0.63, 95% CI 0.37-1.10) and major bleeding (OR 0.77, 95% CI 0.41-1.44) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Two separate pooled analyses of patients with DVT who were treated with
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         (EINSTEIN trials) [
         <a href="#rid41">
          41
         </a>
         ] or
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         (RECOVER trials) [
         <a href="#rid42">
          42
         </a>
         ] reported rates of recurrence and bleeding that were no different between patients with cancer who were treated with DOACs or
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . However, most of the "cancer" patients had completed therapy or had a past history of cancer rather than "active" cancer upon entry into the trials. Thus, there was a selection bias such that patients in these trials had a lower risk of recurrent thrombosis from the outset.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A post-hoc analysis of the AMPLIFY trial reported outcomes in patients who had cancer and were treated with
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         as compared with standard anticoagulation (ie, LMW heparin followed by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) [
         <a href="#rid43">
          43
         </a>
         ]. Among those with active malignancy receiving apixaban, similar rates of recurrent VTE (4 versus 6 percent; RR 0.56, 95% CI 0.13-2.17) and bleeding (2 versus 5 percent; RR 0.45, 95% CI 0.08-2.46) were reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DOAC dosing
         </strong>
         – Doses of the factor Xa inhibitors are similar in patients with cancer-associated thrombosis to those in patients without cancer. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Direct thrombin and factor Xa inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4205190293">
         <span class="h3">
          Low molecular weight heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         LMW heparin is a monotherapeutic agent with long standing established efficacy in patients with cancer-associated VTE. LMW heparin has been compared with DOACs,
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH), and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . No study has directly compared different LMW heparins with each other. However, in clinical practice in the United States,
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         or
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         are the most commonly used agents. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">
          "Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LMW heparin versus DOACS
         </strong>
         – Trials that compared LMW heparin with a DOAC are discussed above. (See
         <a class="local">
          'Direct oral anticoagulant mono- or dual therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LMW heparin and IV UFH
         </strong>
         – Data consistently show similar efficacy of LMW heparin compared with UFH as an
         <strong>
          initial
         </strong>
         anticoagulant for the treatment of cancer-associated VTE. In a meta-analysis of 15 randomized controlled trials, LMW heparin as
         <strong>
          initial
         </strong>
         therapy in cancer-related VTE was associated with a possible reduction in mortality at three months as compared with UFH (RR 0.66, 95% CI 0.40-1.1; 57 fewer deaths per 1000, 95% CI 101 fewer to 17 more; moderate-certainty evidence) [
         <a href="#rid44">
          44
         </a>
         ]. There was no difference in the risk of recurrent VTE or bleeding events.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LMW heparin versus
         </strong>
         <strong>
          warfarin
         </strong>
         – Randomized trials and meta-analyses have demonstrated superiority of LMW heparin over
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         [
         <a href="#rid11">
          11,26,39,44-54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The largest of the meta-analyses (eight randomized trials of 2327 patients) reported reduced rates of recurrent VTE with LMW heparin compared with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (risk ratio 0.58, 95% CI 0.43-0.77), a benefit that occurred without a survival advantage [
         <a href="#rid39">
          39
         </a>
         ]. In addition, no difference in major bleeding events or reports of thrombocytopenia were reported between the groups. However, the quality of evidence was low for mortality, major bleeding, and minor bleeding, and moderate for recurrent VTE.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Two sentinel randomized trials concur with the meta-analysis above:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In one randomized trial (CLOT),
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         compared with LMW heparin followed by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         resulted in a reduction in the rate of recurrent VTE at six months (9 versus 17 percent) without an increase in the rate of major bleeding (6 versus 4 percent) or overall mortality (39 versus 41 percent) [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In another trial (CATCH),
         <a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">
          tinzaparin
         </a>
         compared with LMW heparin followed by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         also resulted in a lower rate of recurrent VTE that was not statistically significant (7 versus 11 percent) at six months, without an increase in mortality or rates of major bleeding [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LMW heparin versus
         </strong>
         <strong>
          fondaparinux
         </strong>
         – Data suggest that LMW heparin is superior to
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         , the details of which are discussed separately. (See
         <a class="local">
          'Fondaparinux'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LMW heparin dosing
         </strong>
         – Dosing of LMW heparin is similar to that in patients without cancer, the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Low molecular weight heparin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         While some early trials suggested that LMW heparin led to a survival advantage in cancer patients with and without VTE [
         <a href="#rid55">
          55-60
         </a>
         ], this potential benefit of LMW heparin has not been confirmed, particularly in the extended-therapy setting [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2215462111">
         <span class="h2">
          Second-line options
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second line options include UFH (followed by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) and
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         , both of which may be used in select circumstances.
        </p>
        <p class="headingAnchor" id="H54052847">
         <span class="h3">
          Unfractionated heparin followed by warfarin
         </span>
         <span class="headingEndMark">
          —
         </span>
         UFH and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , while used commonly in the past, have now been surpassed by LMW heparin and DOACs (specifically factor Xa inhibitors), respectively. However, they are still appropriate to use in select circumstances. Examples include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with severe renal insufficiency – (see
         <a class="local">
          'Renal failure'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Renal failure'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemodynamically unstable patients (UFH) – (see
         <a class="local">
          'Hemodynamically unstable patients'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Hemodynamic instability'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with marked obesity (eg, &gt;150 kg) – (see
         <a class="local">
          'Obesity'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Obesity or poor subcutaneous absorption'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients in whom discontinuation or reversal of anticoagulation is anticipated (UFH) – (see
         <a class="local">
          'Anticipated discontinuation or reversal of anticoagulation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Anticipated need for discontinuation or reversal'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with an extensive clot burden (eg, massive pulmonary embolism [PE], phlegmasia cerulea dolens) (UFH) – (see
         <a class="local">
          'Extensive clot burden'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Extensive clot burden'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients in whom tight regulation of anticoagulation using readily available tests (ie, partial thromboplastin time or anti-factor Xa levels for heparin and prothrombin time/international normalized ratio [for
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ]) is required (eg, those with a bleeding diathesis in whom an atypical range of anticoagulation is targeted).
        </p>
        <p>
        </p>
        <p>
         Data comparing UFH and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         with LMW heparin are discussed above. (See
         <a class="local">
          'Low molecular weight heparin'
         </a>
         above.)
        </p>
        <p>
         Dosing of UFH and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         is similar to that in patients without cancer, the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Unfractionated heparin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Transitioning to maintenance therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Warfarin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H47198011">
         <span class="h3">
          Fondaparinux
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          Fondaparinux
         </a>
         , a synthetic pentasaccharide, is infrequently used in patients with cancer-associated VTE but may be considered in those with heparin-induced thrombocytopenia who need parenteral anticoagulation. (See
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia", section on 'Fondaparinux'
         </a>
         .)
        </p>
        <p>
         In patients with cancer,
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         has only been compared with LMW heparin as an initial anticoagulant prior to the administration of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and has not been compared with LMW heparin in the extended-treatment setting. In a post-hoc analysis of two randomized trials of acute cancer-associated VTE, patients treated initially with fondaparinux (followed by vitamin K antagonists) had higher rates of recurrence at three months with no difference in bleeding rates, when compared with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         (followed by vitamin K antagonists; 12.7 versus 5.5 percent) [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         Dosing of
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         is similar to that in patients without cancer, the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Fondaparinux'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">
          "Fondaparinux: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H335044031">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Principles of anticoagulant selection in special populations of patients with cancer-associated VTE are similar to that in patients without cancer. Agent choice in these populations is mostly discussed in the linked sections below.
        </p>
        <p class="headingAnchor" id="H2690407374">
         <span class="h2">
          Contraindications: Inferior vena cava filter
         </span>
         <span class="headingEndMark">
          —
         </span>
         When therapeutic anticoagulation is absolutely contraindicated (eg, active bleeding), we evaluate patients for placement of an inferior vena cava (IVC) filter. Importantly, an IVC filter should
         <strong>
          not routinely
         </strong>
         be placed for the initial management of VTE in any population, including patients with intracranial malignancy. Importantly, the decision to place a filter should weigh the benefit of preventing death from PE against the risks of recurrent DVT, since the risk of recurrent DVT is higher in those in whom a filter is placed in the absence of anticoagulation. (See
         <a class="local">
          'Management of recurrence'
         </a>
         below and
         <a class="local">
          'Bleeding risk'
         </a>
         below.)
        </p>
        <p>
         Although retrospective cohort studies have found a lower fatality rate in some patients with cancer-associated VTE who had IVC filters compared with those with cancer-associated VTE who did not have an IVC filter placed [
         <a href="#rid62">
          62,63
         </a>
         ], there are no randomized trials that have studied the safety and efficacy of IVC filters in the treatment and prevention of VTE in patients with cancer.
        </p>
        <p>
         Studies performed in the general population have reported an increased risk of DVT (see
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Inferior vena cava filter'
         </a>
         ). Observational studies of patients with cancer-associated VTE report a similar increased DVT risk with IVC filters. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective analysis of patients, patients with cancer-associated DVT in whom an IVC filter was placed had a higher rate of recurrence compared with those who did not have a filter placed (32 versus 17 percent) [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective series of 274 patients undergoing surgery for ovarian cancer, one-half of whom had a newly diagnosed VTE, patients who had a filter placed for VTE had an increased rate of recurrent DVT (25 versus 7.2 percent) and decreased overall survival (22 versus 47 months) compared with patients who had VTE in whom no filter was placed [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1470324904">
         <span class="h2">
          Renal failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with cancer-associated VTE who have severe renal insufficiency (eg, creatinine clearance &lt;30 mL/minute) and in whom renally dosed anticoagulants are contraindicated, IV UFH followed by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         is typically used. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Renal failure'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Warfarin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16855.html" rel="external">
          "Anticoagulation for continuous kidney replacement therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p>
         For those unable to ingest or absorb
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , renally dosed LMW heparin with monitoring of anti-factor Xa levels or SC UFH are alternatives.
        </p>
        <p class="headingAnchor" id="H2193867904">
         <span class="h2">
          Hemodynamically unstable patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV UFH is our preferred anticoagulant in those who are hemodynamically unstable since thrombolysis, an interventional procedure, or surgery may need to be considered. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Hemodynamically unstable'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H83123005">
         <span class="h2">
          Anticipated discontinuation or reversal of anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients in whom a need to discontinue or reverse anticoagulation is anticipated in the near future, we prefer UFH due to its shorter half-life as compared with other anticoagulant therapies. (See
         <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">
          "Risks and prevention of bleeding with oral anticoagulants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H731669088">
         <span class="h2">
          Extensive clot burden
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV UFH is our preferred anticoagulant for those patients with extensive DVT (eg, phlegmasia cerulea dolens), or those with massive or submassive PE. This choice is based upon an anticipated need for a procedural or surgical intervention as well as the ease with which it can be monitored in the laboratory. In addition, DOACs and LMW heparin have not been rigorously evaluated in this population. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Hemodynamically unstable'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121197.html" rel="external">
          "Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3963740270">
         <span class="h2">
          Incidental and small subsegmental pulmonary embolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic PE and small subsegmental PE (SSPE) are sometimes diagnosed on interval computed tomography (CT) scans done for cancer restaging or other reasons. Despite limited data, we generally consider incidental PE and SSPE in patients with cancer as an indication for therapeutic anticoagulation. This preference is based upon the presumption that in this population in the absence of therapeutic anticoagulation, there is a high incidence of developing symptomatic PE in the future due to clot extension or recurrence.
        </p>
        <p>
         Symptoms may be more common than originally thought among those diagnosed incidentally by CT. One retrospective review of 59 patients with unsuspected PE discovered during routine staging for cancer reported that 75 percent of patients had symptoms consistent with PE [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         In patients with incidental or subsegmental PE in association with cancer, limited data suggest a high recurrence rate despite anticoagulation, ranging from 4.3 to 7.9 percent. Although adequate comparison with patients with incidental or subsegmental PE in the absence of cancer have not been published, these rates are higher than that in general population (eg, ≤1 percent on anticoagulation at three months) [
         <a href="#rid63">
          63-67
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one prospective observational study of 695 patients with active cancer and a diagnosis of incidental PE, the recurrence rate was 6 percent at one year despite anticoagulation, and there was no difference between those with subsegmental or more proximal emboli [
         <a href="#rid64">
          64
         </a>
         ]. The bleeding rate was also high at 6 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a post-hoc analysis of a trial that compared
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         with
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         in patients with cancer, the recurrence rate in patients with incidental PE was 7.9 percent and the bleeding rate was 6.6 percent [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another post-hoc analysis of a second randomized trial that compared
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         in the same population, recurrence rate was 4.3 percent in those who had PE as an incidental finding on imaging and 5.3 percent had major bleeding [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Further data on the incidence and management of incidental and subsegmental PE in patients
         <strong>
          without
         </strong>
         cancer are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Patients with subsegmental PE'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H841898019">
         <span class="h2">
          Distal deep venous thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with active cancer, we initiate treatment with anticoagulation, unless there is a contraindication. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Evidence of or risk factors for proximal extension'
         </a>
         .)
        </p>
        <p>
         Data describing outcomes in patients with cancer-associated distal DVT are limited. One registry study of 886 patients with cancer-associated distal DVT reported that the adjusted risks of death, VTE recurrence, or major bleeding were similar in patients with cancer-associated proximal DVT [
         <a href="#rid68">
          68
         </a>
         ]. However, more patients with cancer-associated proximal DVT developed fatal PE (risk difference 0.40 percent, 95% CI 0.23-0.58).
        </p>
        <p class="headingAnchor" id="H2667587274">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pregnant women with acute VTE, adjusted-dose SC LMW heparin is the preferred agent for initial anticoagulation because it has a more favorable safety profile, especially when compared with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and DOACs. (See
         <a class="medical medical_review" href="/z/d/html/1350.html" rel="external">
          "Venous thromboembolism in pregnancy and postpartum: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">
          "Use of anticoagulants during pregnancy and postpartum"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H194976050">
         <span class="h2">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no preferred agent in patients with class 2 or 3 obesity.
        </p>
        <p>
         Therapeutic anticoagulation can be assured with IV UFH and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . IV UFH is an alternative to SC LMW heparin when SC absorption is potentially poor (eg, massive edema, anasarca).
        </p>
        <p>
         Doses for LMW heparin in patients with class 2 or 3 obesity are found in the table  (
         <a class="graphic graphic_table graphicRef65464" href="/z/d/graphic/65464.html" rel="external">
          table 3
         </a>
         ), although therapeutic efficacy of such dosing is unclear. (See
         <a class="medical medical_review" href="/z/d/html/584.html" rel="external">
          "Intensive care unit management of patients with obesity", section on 'Anticoagulants'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Obesity or poor subcutaneous absorption'
         </a>
         .)
        </p>
        <p>
         Dosing for DOACs in patients with class 2 or 3 obesity is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Dosing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H489600742">
         <span class="h2">
          Thrombosis in other locations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of thrombosis in other locations is discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with catheter-related upper extremity venous thrombosis – (see
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults", section on 'Treatment'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with splanchnic or visceral vein thrombus – (see
         <a class="medical medical_review" href="/z/d/html/88016.html" rel="external">
          "Epidemiology and pathogenesis of portal vein thrombosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3579.html" rel="external">
          "Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88014.html" rel="external">
          "Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2509395562">
         <span class="h1">
          CANCER-SPECIFIC ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H1306742543">
         <span class="h2">
          Specific cancers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain cancers may require special consideration including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with intracranial malignancy who may be at increased risk of significant complications from bleeding – (see
         <a class="medical medical_review" href="/z/d/html/5201.html" rel="external">
          "Treatment and prevention of venous thromboembolism in patients with brain tumors"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with pancreatic and upper gastrointestinal cancer who are at increased risk of recurrence and bleeding, respectively – (see
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer", section on 'Venous thromboembolism'
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Rates of recurrence and bleeding may vary depending upon the cancer site. In one post-hoc analysis of a randomized trial that compared
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         with
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         [
         <a href="#rid23">
          23
         </a>
         ], rates of VTE recurrence were 11 percent in patients with gynecological, 9 percent with gastrointestinal, 7 percent with genitourinary, and 6 percent with lung cancer [
         <a href="#rid24">
          24
         </a>
         ]; rates were lower rates in the other sites of cancer. Rates of major bleeding were highest in those with genitourinary cancer (7 percent) and gastrointestinal cancer (5 percent). Although rates or recurrence were lower with apixaban at each site, none was statistically significant and rates of bleeding were similar.
        </p>
        <p class="headingAnchor" id="H3182304224">
         <span class="h2">
          Thrombocytopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with cancer frequently have thrombocytopenia placing them at increased risk of bleeding on anticoagulants.
        </p>
        <p>
         Thrombocytopenia is not a contraindication to anticoagulation for individuals with platelet counts &gt;50,000/microL. However, anticoagulation is typically contraindicated in those with platelet counts &lt;20,000/microL.
        </p>
        <p>
         For many individuals with cancer and acute VTE who have platelet counts between 20,000 and 50,000/microL, the decision to anticoagulate should be individualized and based upon the risk of serious complications from VTE and the risk of bleeding associated with anticoagulation, especially when anticoagulant dose modifications or platelet transfusions are used.
        </p>
        <p>
         This subject and anticoagulation in patients with heparin-induced thrombocytopenia are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/117208.html" rel="external">
          "Anticoagulation in individuals with thrombocytopenia", section on 'Cancer-associated VTE'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia", section on 'Anticoagulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H691645528">
         <span class="h2">
          Arterial thromboembolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arterial thromboembolism is less common than venous thromboembolism in patients with cancer. Retrospective cohort analyses in patients with cancer suggest that the incidence of arterial thromboembolism ranges from 2 to 6 percent [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p>
         In patients with malignancy, the most common sources for arterial thromboembolism are nonbacterial thrombotic endocarditis and paradoxical embolism arising from deep venous thrombosis [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/91781.html" rel="external">
          "Nonbacterial thrombotic endocarditis"
         </a>
         .)
        </p>
        <p>
         Embolism to the digits, brain, or solid organs (in the absence of a source) can also be a paraneoplastic manifestation of solid tumors and myeloproliferative disorders [
         <a href="#rid72">
          72,73
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4491.html" rel="external">
          "Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Thrombosis and hemorrhage'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">
          "Clinical manifestations and diagnosis of polycythemia vera", section on 'Thrombosis and hemorrhage'
         </a>
         .)
        </p>
        <p>
         We typically anticoagulate patients with cancer-associated arterial thrombosis provided that the patient's bleeding risk is not high and treatment is consistent with the patient's overall management goals.
        </p>
        <p class="headingAnchor" id="H3783363588">
         <span class="h1">
          OUTPATIENT THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         We consider the following as appropriate in patients with cancer-associated VTE:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Deep venous thrombosis (DVT) – Many patients with cancer-associated DVT of the lower extremity are treated as outpatients. We select patients for outpatient treatment using similar principles to those in the noncancer population  (
         <a class="graphic graphic_table graphicRef70140" href="/z/d/graphic/70140.html" rel="external">
          table 4
         </a>
         ), the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Outpatient versus inpatient therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary embolism (PE) – By contrast, we generally treat patients with cancer-associated PE as an inpatient or with observation for a short period of time before discharge (eg, 12 to 24 hours). However, we often treat clinically stable patients with asymptomatic or small subsegmental PE as outpatients. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Outpatient anticoagulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Principles of agent selection are similar to those in patients who do not have malignancy. The most commonly used agent is an oral factor Xa inhibitor. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Outpatient versus inpatient therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H892384374">
         <span class="h1">
          DURATION OF ANTICOAGULATION
         </span>
        </p>
        <p class="headingAnchor" id="H819691711">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         For a first episode of acute VTE in patients with active cancer, anticoagulant therapy should be administered for at least three to six months, provided the bleeding risk is low and no clinically relevant complications from anticoagulation have occurred (bleeding, heparin-induced thrombocytopenia). Considering when to extend beyond this finite period involves clinical judgement and reassessment of the recurrence and bleeding risk. Our general approach is the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In most patients with active cancer and proximal deep venous thrombosis (DVT) or pulmonary embolism (PE), we administer indefinite anticoagulant therapy, unless the bleeding risk is high or VTE was precipitated by a major provoking event such as surgery. Provided the patient has no other justification for indefinite anticoagulation, treatment is typically continued until the patient is in remission or has a major bleeding complication. Whether the intensity of anticoagulant therapy might be lowered after some initial (eg, 6 to 12 months) treatment is the subject of at least one ongoing randomized controlled trial (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03080883&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPGG3%2BOhI2p13FVOSzkvl%2Fih1VCkdaAxYJ1wuR5TiE7zQ%3D%3D&amp;TOPIC_ID=1340" target="_blank">
          NCT03080883
         </a>
         ) [
         <a href="#rid74">
          74
         </a>
         ]. Active cancer is defined by the International Society on Thrombosis and Hemostasis as cancer diagnosed within the previous six months; recurrent, regionally advanced, or metastatic cancer; cancer for which treatment has been administered within six months; or hematologic cancer that is not in complete remission [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The optimal duration of anticoagulant therapy for a patient with cancer-related isolated distal DVT that is not associated with surgery is not known; however, we typically approach such patients similar to cancer patients with proximal DVT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exceptions include those at high bleeding risk, those with a clear provoking event and no other persistent risk factors (eg, surgery, subtherapeutic anticoagulation), patients in remission from their cancer, and patients with a strong preference not to be on extended anticoagulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Follow-up with yearly reevaluation of the benefit/risk ratio for anticoagulation is important for this population to avoid unnecessary morbidity from bleeding or a recurrence. (See
         <a class="local">
          'Follow-up'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         This recommendation is based upon the rationale that patients with active cancer have a high risk of recurrence. (See
         <a class="local">
          'Recurrence risk'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         When selecting patients for extended anticoagulation, we follow the same general principles as in noncancer patients  (
         <a class="graphic graphic_table graphicRef131266" href="/z/d/graphic/131266.html" rel="external">
          table 5
         </a>
         ). Further details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3665260532">
         <span class="h2">
          Recurrence and bleeding risk assessment for patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with cancer-associated VTE, we individualize recurrence and bleeding risk assessment and take into consideration the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General factors that apply to all patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cancer-specific factors
        </p>
        <p>
        </p>
        <p>
         In this section, we will discuss factors that are common in or specific to patients with cancer. Factors used to assess all patients with VTE for indefinite anticoagulation are provided separately  (
         <a class="graphic graphic_table graphicRef131266" href="/z/d/graphic/131266.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1674761010">
         <span class="h3">
          Recurrence risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         VTE recurrence rates are high in patients with active cancer despite adequate anticoagulation [
         <a href="#rid51">
          51,75-80
         </a>
         ]. However, the risk varies considerably. Factors that may influence this risk include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Active versus in-remission cancer
         </strong>
         – Patients with
         <strong>
          active
         </strong>
         cancer have a higher risk for recurrence on therapeutic anticoagulation compared with those in remission. Although the lower risk among those in remission may justify discontinuing anticoagulation, the risk of recurrence in this patient population is unknown. The definition of active cancer is provided above. (See
         <a class="local">
          'Duration of anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors for subtherapeutic anticoagulation
         </strong>
         – For patients on
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , subtherapeutic anticoagulation is a common cause of recurrence. In patients with cancer, it is particularly common due to decreased absorption, cessation of therapy for procedures or bleeding, and varying dose requirements (eg, drug interactions), all of which contribute to longer periods of time outside of the target therapeutic range.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – Other cancer-specific factors that may increase the recurrence risk in patients with cancer include the following [
         <a href="#rid60">
          60,81
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Concomitant anticancer medications (eg, hormonal medications,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Common risk factors in patients with cancer (eg, immobility, pathologic fracture, recent surgery or invasive procedures, presence of a central venous access line, oral intolerance of medications due to nausea/vomiting).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Younger age (&lt;65 years).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         PE at presentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Newly diagnosed cancer (&lt;3 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Specific cancer site (eg, pancreatic cancer has one of the highest rates of thrombosis). (See
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Models have been proposed to help identify patients with cancer and acute VTE who are at greatest risk of recurrence. However, they are not widely used, and further studies are needed to examine whether they can be used to select patients who may benefit from extended anticoagulation [
         <a href="#rid76">
          76
         </a>
         ]. Data that support using models such as the Khorana score to calculate the risk of VTE in patients with cancer who have
         <strong>
          not
         </strong>
         yet had VTE are described separately. (See
         <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">
          "Risk and prevention of venous thromboembolism in adults with cancer", section on 'VTE risk assessment/Khorana score'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2956583495">
         <span class="h3">
          Bleeding risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of VTE with anticoagulation is associated with higher rates of bleeding than in patients without cancer [
         <a href="#rid2">
          2-9
         </a>
         ]. Rates of major bleeding range from 6.5 to 18 percent [
         <a href="#rid5">
          5,6,51
         </a>
         ]. In a trial of 334 patients treated with
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         , rates of bleeding were highest in the first month and declined over the subsequent 11 months (4 versus 1 percent) [
         <a href="#rid51">
          51
         </a>
         ]. Another study reported that the case fatality rates from bleeding were 0.8 per 100 patient-years of follow-up [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         Cited risk factors for bleeding in patients with cancer overlap with those in patients without cancer  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 6
         </a>
         ) and include the following [
         <a href="#rid81">
          81,83,84
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older age (&gt;65 years)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supra therapeutic anticoagulation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher-intensity anticoagulation regimens (see
         <a class="local">
          'Management of recurrence'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior gastrointestinal bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immobilization
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of metastases
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Creatinine clearance &lt;30 mL/minute
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intracranial neoplasms
        </p>
        <p>
        </p>
        <p>
         Risk factors for bleeding in the general population and assessment for bleeding risk when considering indefinite anticoagulation are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Risk of bleeding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Assessing the risk of bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2885051910">
         <span class="h2">
          Agent selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agent selection for extended anticoagulation is similar to that for initial therapy, which is generally an oral factor Xa inhibitor (ie, a direct oral anticoagulant) or low molecular weight heparin. Agent selection for indefinite anticoagulation in patients without cancer is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Low-intensity regimens following a finite course'
         </a>
         .)
        </p>
        <p>
         There is a paucity of data evaluating extended anticoagulation beyond six months in patients with active cancer. In a post-hoc analysis of one major trial [
         <a href="#rid26">
          26
         </a>
         ] that compared
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         with
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         in patients with active cancer, VTE recurrence rates were no different between the groups (&lt;0.7 percent for edoxaban versus 1.1 percent for dalteparin) [
         <a href="#rid85">
          85
         </a>
         ]. Similar rates of major bleeding were also reported (1.7 percent for edoxaban versus 1.1 percent for dalteparin).
        </p>
        <p>
         We do not administer low-intensity regimens in patients with active cancer since the baseline risk of recurrence is too high and lower-intensity regimens have not been studied in this population. Data to support low-intensity regimens in select patients without cancer are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Low-intensity regimens following a finite course'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H494695761">
         <span class="h1">
          SWITCHING ANTICOAGULANTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interruptions should be limited, if feasible, especially during the first three months of anticoagulation. However, anticoagulants may need to be changed for medical reasons or patient preference. Reasons for changing anticoagulants and how best to transition are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Switching anticoagulants during therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11407413">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with cancer-associated VTE, follow-up is important since the course is often punctuated by issues that affect continuation or discontinuation of anticoagulation [
         <a href="#rid2">
          2-9
         </a>
         ]. This includes recurrence, bleeding, procedures, thrombocytopenia, new medications, conditions that affect oral intake or drug absorption, cancer progression, or achievement of remission.
        </p>
        <p>
         All patients on anticoagulation should be monitored clinically for recurrences and bleeding, and for the development of adverse effects or conditions that affect the metabolism of the administered anticoagulant. During evaluation, we carefully weigh the benefit of preventing VTE recurrence (see
         <a class="local">
          'Recurrence risk'
         </a>
         above) against the bleeding risk (see
         <a class="local">
          'Bleeding risk'
         </a>
         above), while taking into consideration the type of cancer, burden of disease, treatment received, patient preference, and life expectancy.
        </p>
        <p class="headingAnchor" id="H1705439850">
         <span class="h1">
          MANAGEMENT OF RECURRENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         VTE recurrence is more common in patients with cancer compared with patients who do not have cancer (see
         <a class="local">
          'Recurrence risk'
         </a>
         above). For patients who develop a recurrence despite therapeutic anticoagulation, involvement of a hematologist and/or oncologist is prudent.
        </p>
        <p>
         The causes and principles of management are similar to patients without cancer. In brief, the etiology should be identified and treated accordingly (eg, subtherapeutic anticoagulation, nonadherence, impaired oral absorption, marked obesity, ongoing thrombotic stimuli). (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Management of recurrence on therapy'
         </a>
         .)
        </p>
        <p>
         The following is a strategy that can be applied to patients with and without cancer who have recurrence
         <strong>
          despite
         </strong>
         therapeutic anticoagulation and in whom a reversible etiology cannot be identified. This strategy involves one or both of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Switching or escalating anticoagulant therapy
         </strong>
         – A common management strategy involves using an alternate agent or increasing the dose or frequency of administration of the anticoagulant. Such management is empiric, as randomized trials addressing this problem are lacking, and consultation with a thrombosis specialist is advised. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a recurrence on the recommended dose of a direct oral anticoagulant or
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         with an international normalized ratio (INR) in the therapeutic range (ie, 2 to 3), we generally switch to low molecular weight (LMW) heparin at therapeutic doses (see
         <a class="local">
          'Low molecular weight heparin'
         </a>
         above). Rarely, for patients on warfarin in whom switching to LMW heparin or an oral factor Xa inhibitor is not feasible, LMW heparin can be used followed by warfarin with a higher INR target range (eg, 2.5 to 3.5).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with recurrence on a single daily dose of LMW heparin, we switch to every-12-hour administration at a therapeutic dose or increase to 120 percent of the therapeutic dose, knowing that the bleeding risk is increased with the latter. Another option would be to switch to either
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         or
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         at therapeutic doses, but there is little published experience with this approach. (See
         <a class="local">
          'Direct oral anticoagulant mono- or dual therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are limited data to support this strategy and larger, prospective studies with longer follow-up are needed. One retrospective study evaluated the efficacy of escalating the dose of LMW heparin in 70 patients with active cancer who developed a documented episode of recurrent VTE while receiving anticoagulation (LMW heparin or
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) [
         <a href="#rid86">
          86
         </a>
         ]. Twenty-one percent of patients were on therapeutic doses of LMW heparin and were increased to 120 percent of the therapeutic dose for at least four weeks. The remaining patients, who were on subtherapeutic doses of LMW heparin (46 percent) or were warfarin failures (33 percent), were switched over to therapeutic LMW heparin. At three months, 8.6 percent of patients had a recurrent episode of VTE within two months. Among those treated with an increased dose of LMW heparin, no further recurrences were reported during the three-month follow-up period. Bleeding complications were reported in 4 percent of patients, with only one major bleed (in a patient with intracranial malignancy). Deaths in this study were not related to either recurrent VTE or bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inferior vena cava filter
         </strong>
         – For patients with VTE recurrence in whom anticoagulation therapy is maximized, we consider adding an inferior vena cava (IVC) filter to therapeutic anticoagulation. For patients with recurrent cancer-associated VTE in whom anticoagulation has been associated with bleeding complications, we also consider an IVC filter. Data supporting the placement of an IVC filter are limited and discussed above. (See
         <a class="local">
          'Contraindications: Inferior vena cava filter'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2958203442">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">
          "Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">
          "Society guideline links: Anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – Anticoagulation is the cornerstone of therapy for cancer-associated venous thromboembolism (VTE). However, anticoagulation in this population is complicated by higher than usual rates of recurrent VTE and bleeding and is commonly impacted by comorbidities, procedures, and medication interactions. (See
         <a class="local">
          'Principles of therapy'
         </a>
         above and
         <a class="local">
          'Agent choice'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agent selection
         </strong>
         – Choosing among the agents is dependent upon several factors that are described in the tables  (
         <a class="graphic graphic_table graphicRef81646" href="/z/d/graphic/81646.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Selecting among the agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach is the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Most patients
         </strong>
         – For most hemodynamically stable patients with cancer-associated VTE who do not have severe renal insufficiency (eg, creatinine clearance &lt;30 mL/minute) or a contraindication, we suggest an oral factor Xa inhibitor (ie, a direct oral anticoagulant) rather than low molecular weight (LMW) heparin (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ) or conventional anticoagulation (ie, intravenous
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         followed by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This choice is based upon data that show similar efficacy and safety for oral factor Xa inhibitors and LMW heparin in cancer-associated VTE. While several factors influence agent selection, factor Xa inhibitors are frequently chosen to avoid the need for daily injections that are required for LMW heparin. (See
         <a class="local">
          'First-line options'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Factor Xa inhibitors
         </strong>
         – Among the factor Xa inhibitors, we suggest
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         , as an oral
         <strong>
          monotherapy
         </strong>
         option (ie, administered without an initial five days of parenteral LMW heparin) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This preference is based upon a randomized trial that reported similar efficacy and safety compared with LMW heparin. However, apixaban has the disadvantage of twice-daily dosing.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         As an alternative, the factor Xa inhibitors
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         (a once-daily monotherapy agent) or
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         (a once-daily dual-therapy agent; ie, administered with an initial five days of parenteral heparin) can be used. However, we typically avoid these two agents in patients with upper gastrointestinal cancers since more bleeding has been reported with these agents than with
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         or LMW heparin. (See
         <a class="local">
          'Direct oral anticoagulant mono- or dual therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          LMW heparin
         </strong>
         – LMW heparin may be an alternative in patients who cannot take a factor Xa inhibitor (eg, not covered on insurance). Several LMW heparin formulations are available. While they have not been compared with one another,
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         or
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         are used most commonly in the United States. (See
         <a class="local">
          'Low molecular weight heparin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Special populations
         </strong>
         – For patients with hemodynamic instability or severe renal insufficiency, considerations regarding agent selection are similar to those in patients without cancer. Other cancer-specific issues requiring special consideration include intracranial malignancy and thrombocytopenia. Agent selection in specific populations is discussed separately. (See
         <a class="local">
          'Special populations'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Special populations'
         </a>
         and
         <a class="local">
          'Cancer-specific issues'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outpatient therapy
         </strong>
         – We typically treat patients with cancer and uncomplicated deep venous thrombosis (DVT; eg, DVT without concomitant pulmonary embolism [PE]) as outpatients using similar principles to those in the noncancer population  (
         <a class="graphic graphic_table graphicRef70140" href="/z/d/graphic/70140.html" rel="external">
          table 4
         </a>
         ). Most patients with cancer who have PE are admitted or undergo a short observation period. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Outpatient versus inpatient therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Outpatient anticoagulation'
         </a>
         and
         <a class="local">
          'Outpatient therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of anticoagulation
         </strong>
         – For most patients with active cancer-associated VTE, we suggest extending therapy beyond the conventional three-to-six-month period (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), unless the bleeding risk is high or VTE was precipitated by a major provoking event such as surgery. Provided the patient has no other justification for indefinite anticoagulation, treatment is typically continued until the patient is in remission or has a major bleeding complication. (See
         <a class="local">
          'Duration of anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         This recommendation is based upon the rationale that most of these patients have a high risk of recurrence such that the benefit of VTE prevention outweighs the risk of bleeding with anticoagulant therapy. However, the decision is challenging since this population is also at a higher risk of bleeding on anticoagulant therapy and patients may have personal factors that weigh into the decision (eg, life expectancy)  (
         <a class="graphic graphic_table graphicRef81646" href="/z/d/graphic/81646.html" rel="external">
          table 1
         </a>
         ). Thus, we individualize the approach to risk assessment using similar principles in patients without cancer. (See
         <a class="local">
          'Recurrence risk'
         </a>
         above and
         <a class="local">
          'Bleeding risk'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Clinical assessment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Agent selection is similar to that for initial selection (ie, oral factor Xa inhibitor or LMW heparin). We do not administer low-intensity regimens in patients with active cancer. (See
         <a class="local">
          'Agent selection'
         </a>
         above and
         <a class="local">
          'Switching anticoagulants'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Switching anticoagulants during therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – All patients with cancer on anticoagulant therapy should be monitored clinically since their course is often punctuated with issues that affect continuation or discontinuation of anticoagulation including VTE recurrence, bleeding, procedures, thrombocytopenia, new medications, conditions that affect oral intake or drug absorption, local and metastatic progression, or achievement of remission  (
         <a class="graphic graphic_table graphicRef81646" href="/z/d/graphic/81646.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Managing recurrences
         </strong>
         – Management options for those who recur despite therapeutic anticoagulation include switching to LMW heparin for patients taking an oral anticoagulant or escalation of the dose of LMW heparin for those already on LMW heparin. Involvement of a hematologist is prudent. (See
         <a class="local">
          'Management of recurrence'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002; 3:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sallah S, Husain A, Sigounas V, et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 2004; 10:7238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18:3078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100:3484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med 2001; 110:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001; 111:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005; 128:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monreal M, Falgá C, Valdés M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4:1950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160:e545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw 2015; 13:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streiff MB, Holmstrom B, Angelini D, et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw 2018; 16:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16:1891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20:e566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022; 23:e334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes HM, Bain KT, Zalpour A, et al. Predictors of anticoagulation in hospice patients with lung cancer. Cancer 2010; 116:4817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Winter MA, Dorresteijn JAN, Ageno W, et al. Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. Thromb Haemost 2022; 122:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med 2020; 382:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agnelli G, Muñoz A, Franco L, et al. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. Thromb Haemost 2022; 122:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 2018; 36:2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020; 18:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ageno W, Vedovati MC, Cohen A, et al. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thromb Haemost 2021; 121:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houghton DE, Vlazny DT, Casanegra AI, et al. Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. Mayo Clin Proc 2021; 96:2793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mantha S, Laube E, Miao Y, et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 2017; 43:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. Chest 2022; 161:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulati S, Eckman MH. Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. Ann Intern Med 2023; 176:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossel A, Robert-Ebadi H, Combescure C, et al. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. PLoS One 2019; 14:e0213940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuentes HE, McBane RD 2nd, Wysokinski WE, et al. Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis. Mayo Clin Proc 2019; 94:2444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. Thromb Haemost 2020; 120:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 2020; 136:1433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riaz IB, Fuentes HE, Naqvi SAA, et al. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clin Proc 2022; 97:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrag D, Uno H, Rosovsky R, et al. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. JAMA 2023; 329:1924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahale LA, Hakoum MB, Tsolakian IG, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev 2018; 6:CD006650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman S, Goldhaber SZ, Kearon C, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015; 13:2187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akl EA, Kahale LA, Hakoum MB, et al. Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database Syst Rev 2017; 9:CD006652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akl EA, Kahale L, Terrenato I, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2014; :CD006466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noble SI, Shelley MD, Coles B, et al. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Maître A, Ding K, Shepherd FA, et al. Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. J Thorac Oncol 2009; 4:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015; 13:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA 2015; 314:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laporte S, Bertoletti L, Romera A, et al. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients. Thromb Res 2012; 130:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23:2123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22:1944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23:2130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006; 81:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Doormaal FF, Di Nisio M, Otten HM, et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011; 29:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Napolitano M, Saccullo G, Malato A, et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol 2014; 32:3607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Doormaal FF, Raskob GE, Davidson BL, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost 2009; 101:762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein PD, Matta F, Sabra MJ. Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism. Am J Med 2013; 126:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giustozzi M, Connors JM, Ruperez Blanco AB, et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. J Thromb Haemost 2021; 19:2751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraaijpoel N, Bleker SM, Meyer G, et al. Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. J Clin Oncol 2019; 37:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulder FI, Di Nisio M, Ay C, et al. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J 2020; 55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connell CL, Boswell WD, Duddalwar V, et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 2006; 24:4928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peris M, Jiménez D, Maestre A, et al. Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. Eur Respir J 2016; 48:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galanaud JP, Trujillo-Santos J, Bikdeli B, et al. Clinical Presentation and Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis. J Clin Oncol 2023; :JCO2300429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168:2377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iguchi Y, Kimura K, Kobayashi K, et al. Ischaemic stroke with malignancy may often be caused by paradoxical embolism. J Neurol Neurosurg Psychiatry 2006; 77:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahé I, Agnelli G, Ay C, et al. Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. Thromb Haemost 2022; 122:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albertsen IE, Nielsen PB, Søgaard M, et al. Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. Am J Med 2018; 131:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heit JA, Lahr BD, Petterson TM, et al. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood 2011; 118:4992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman S, Zondag M, Linkins L, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost 2015; 13:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moik F, Colling M, Mahé I, et al. Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review. J Thromb Haemost 2022; 20:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdulla A, Davis WM, Ratnaweera N, et al. A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer. Thromb Haemost 2020; 120:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999; 107:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kooiman J, den Exter PL, Cannegieter SC, et al. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment. J Thromb Haemost 2013; 11:1968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Nisio M, van Es N, Carrier M, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost 2019; 17:1866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7:760.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1340 Version 91.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17319909" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11908507" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cancer and the prothrombotic state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15534097" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10963635" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393647" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11343664" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11566456" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15667530" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Management of thrombosis in cancer: primary prevention and secondary prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16961602" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31381464" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34352278" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26358792" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23217107" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30442731" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30027649" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31473594" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31492632" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33570602" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35772465" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36638869" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20572034" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Predictors of anticoagulation in hospice patients with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34544170" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32223112" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34530482" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29746227" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29231094" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31630479" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33202447" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34425962" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27696084" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34627853" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36571839" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30897142" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31685262" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32365386" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32396939" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34172290" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37266947" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29920657" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25211264" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24053656" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25739680" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26407753" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28892556" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Parenteral anticoagulation in ambulatory patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24980743" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12853587" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12153376" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17145251" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18510989" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19357539" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25827941" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26284719" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22939430" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17000884" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699480" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15143088" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699479" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The effect of low molecular weight heparin on survival in patients with advanced malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16770976" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21502549" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25267738" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19350123" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23968903" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34260816" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31116676" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31727694" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Clinical implications of incidental venous thromboembolism in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17050877" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27660517" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37471683" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Clinical Presentation and Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16421425" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Thromboembolism in hospitalized neutropenic cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19029504" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16847046" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ischaemic stroke with malignancy may often be caused by paradoxical embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2183357" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The prethrombotic state in cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6375757" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Bleeding and thrombosis in the myeloproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34535037" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10737275" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22679142" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30266273" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21890644" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25851122" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34816583" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18766259" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32289865" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10569295" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Major bleeding after hospitalization for deep-venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24112123" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31271705" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19245418" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
